Buy Sema (G.L.P) 30mg | G.L.P-1 Research Peptide
Sema (G.L.P) 30mg is a synthetic glucagon-like peptide-1 (G.L.P-1) receptor agonist used in laboratory research involving glucose regulation, metabolic signaling, and incretin receptor activity.
Sema (G.L.P) is a modified version of the naturally occurring G.L.P-1 hormone. Its structure allows it to interact with G.L.P-1 receptors while resisting rapid breakdown. Researchers have studied the compound extensively in preclinical experiments and human clinical trials.
The 30mg presentation offered by
Orion Peptide is a research compound intended for laboratory work requiring a larger quantity of Sema (G.L.P). The amount listed describes the nominal vial content, not a recommended dose or an approved medicine.
Sema (G.L.P) has been studied in research involving type 2 diabetes, obesity, cardiovascular outcomes, and related metabolic pathways. These investigations have helped scientists understand how G.L.P-1 receptor signaling influences insulin secretion, glucagon regulation, appetite, and gastric emptying.
Research Use Only: Orion Peptide’s 30mg research compound is not an FDA-approved medication and is not intended for human or veterinary use.
What Is Sema (G.L.P) 30mg?
Sema (G.L.P) is a long-acting G.L.P-1 receptor agonist developed from the human G.L.P-1 peptide sequence.
G.L.P-1 is an incretin hormone released by intestinal cells after food intake. It plays an important role in glucose regulation by influencing insulin and glucagon secretion.
Natural G.L.P-1 has a short biological half-life because enzymes, particularly dipeptidyl peptidase-4 (DPP-4), break it down quickly.
Scientists developed Sema (G.L.P) with specific chemical modifications to improve its resistance to degradation and extend its activity.
These modifications include an amino acid substitution that helps protect the peptide against DPP-4 and a fatty diacid side chain that increases binding to serum albumin.
The resulting molecule has an elimination half-life of approximately one week in humans.
Sema (G.L.P) has become an important reference compound for researchers investigating G.L.P-1 receptor activation and the design of longer-acting peptide analogs.
The
Sema (G.L.P) 30mg research vial from Orion Peptide provides a nominal 30mg quantity of this compound for controlled scientific investigation. Its identity, purity, and actual content should be evaluated using compound-specific analytical documentation.
Sema (G.L.P) 30mg Molecular Specifications
Sema (G.L.P) contains 31 amino acid residues and belongs to the class of modified G.L.P-1 analogs.
| Property |
Details |
| Compound name |
Sema (G.L.P) 30mg |
| Compound |
Sema (G.L.P) |
| Peptide class |
G.L.P-1 receptor agonist |
| CAS number |
910463-68-2 |
| Molecular formula |
C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular weight |
Approximately 4,113.58 g/mol |
| Amino acid length |
31 residues |
| PubChem CID |
56843331 |
| Molecular modification |
C18 fatty diacid side chain |
| Primary research target |
G.L.P-1 receptor |
| Nominal vial content |
30mg |
| Research areas |
Incretin signaling, glucose metabolism, and peptide pharmacology |
| Intended use |
Laboratory research only |
These values refer to the Sema (G.L.P) molecule itself. They do not confirm the composition or purity of an individual manufactured batch.
Chemical reference: PubChem: Sema (G.L.P).
Sema (G.L.P) Structure and Half-Life
Sema (G.L.P) was developed to overcome two limitations of natural G.L.P-1: rapid enzymatic degradation and short circulation time.
The peptide contains three important structural modifications.
1. Protection Against Enzymatic Breakdown
Sema (G.L.P) contains an amino acid substitution at the second position of the G.L.P-1 analog sequence, corresponding to position 8 in the conventional G.L.P-1 numbering system.
This substitution introduces 2-aminoisobutyric acid (Aib).
Aib helps protect the peptide against cleavage by DPP-4, an enzyme responsible for rapidly inactivating natural G.L.P-1.
2. Fatty Diacid Side Chain
A C18 fatty diacid side chain is attached through a linker to the lysine residue corresponding to position 26 in G.L.P-1 numbering.
This modification increases binding to serum albumin.
Albumin binding helps reduce renal clearance and contributes to Sema (G.L.P)’s extended circulation time.
3. Selective Fatty Acid Attachment
Another amino acid change, at position 34 in G.L.P-1 numbering, helps direct the fatty acid modification to the intended attachment site during molecular synthesis.
Together, these structural features contribute to the compound’s pharmacokinetic properties.
How long is Sema (G.L.P)’s half-life?
Clinical pharmacokinetic studies have established an elimination half-life of approximately seven days in humans.
This property is associated with the structure of Sema (G.L.P) and its interaction with circulating albumin.
However, the half-life measured in humans should not automatically be applied to every animal or in vitro research model.
Research reference: Lau J, et al. (2015). Discovery of the Once-Weekly G.L.P-1 Analogue Sema (G.L.P).
Sema (G.L.P) Mechanism of Action
Sema (G.L.P) acts as an agonist of the glucagon-like peptide-1 receptor.
The G.L.P-1 receptor belongs to the G-protein-coupled receptor family and is expressed in several tissues, including pancreatic cells and parts of the nervous system.
When Sema (G.L.P) binds to an appropriate G.L.P-1 receptor, it activates intracellular signaling pathways involved in metabolic regulation.
One of the major pathways involves cyclic adenosine monophosphate, or cAMP.
The process can be summarized as follows:
- Sema (G.L.P) binds to the G.L.P-1 receptor.
- Receptor activation stimulates Gs-protein signaling.
- Adenylyl cyclase activity increases, raising intracellular cAMP.
- Downstream signaling influences cellular responses associated with glucose-dependent insulin secretion and other G.L.P-1 functions.
Scientists investigate these processes to understand how incretin signaling affects different metabolic pathways.
Glucose-Dependent Insulin Secretion
In pancreatic beta cells, G.L.P-1 receptor activation enhances insulin secretion when glucose levels are elevated.
This glucose-dependent mechanism is an important feature of G.L.P-1 receptor pharmacology.
Glucagon Regulation
Sema (G.L.P) can reduce inappropriate glucagon secretion under certain physiological conditions.
Glucagon is a hormone involved in regulating glucose production and release.
Gastric Emptying
G.L.P-1 receptor signaling also influences gastrointestinal motility.
Clinical research has demonstrated that Sema (G.L.P) can delay gastric emptying, although the magnitude of this effect depends on treatment duration and experimental conditions.
Appetite-Related Signaling
G.L.P-1 receptors are involved in neural pathways associated with appetite and food intake.
Sema (G.L.P) has been investigated extensively in clinical research examining these pathways.
These findings relate to the pharmacology of the Sema (G.L.P) molecule. They do not establish that an unapproved research vial is suitable for human administration.
Sema (G.L.P) Research Applications
Sema (G.L.P) has been examined in preclinical experiments and large clinical trials.
The available research covers several areas of metabolic science.
1. G.L.P-1 Receptor Signaling Research
Sema (G.L.P) is useful as a reference compound in studies of G.L.P-1 receptor activation.
Researchers investigate receptor binding, intracellular signaling, and the relationship between peptide structure and receptor activity.
Experimental systems may include appropriately validated cell-based assays and other laboratory models.
2. Glucose Metabolism Research
The relationship between G.L.P-1 receptor activation and glucose regulation has been studied for several decades.
Sema (G.L.P) research has contributed to the understanding of insulin secretion, glucagon signaling, and metabolic feedback systems.
A major focus is how G.L.P-1 receptor activation changes cellular responses under different glucose conditions.
3. Obesity and Appetite Research
Sema (G.L.P) has also been investigated in clinical trials involving body-weight regulation.
The STEP 1 trial, published in 2021, enrolled 1,961 adults with overweight or obesity who did not have diabetes.
Participants received either Sema (G.L.P) or placebo alongside lifestyle intervention during a 68-week study.
The Sema (G.L.P) group experienced a mean body-weight reduction of 14.9%, compared with 2.4% in the placebo group.
Gastrointestinal adverse events were common, and more participants receiving Sema (G.L.P) discontinued treatment because of these events.
These findings come from a controlled clinical trial using a regulated pharmaceutical formulation. They cannot be used to establish the safety, quality, or effectiveness of a research-grade peptide vial.
Research reference: Wilding JPH, et al. (2021). Once-Weekly Sema (G.L.P) in Adults with Overweight or Obesity.
4. Cardiovascular Research
Sema (G.L.P) has been evaluated in cardiovascular outcome trials involving patients with type 2 diabetes and other cardiovascular risk factors.
The SUSTAIN-6 trial investigated cardiovascular outcomes in 3,297 participants with type 2 diabetes.
Over the study period, the primary composite cardiovascular outcome occurred in 6.6% of participants receiving Sema (G.L.P) compared with 8.9% receiving placebo.
The study also identified safety considerations, including a higher rate of diabetic retinopathy complications in the Sema (G.L.P) group.
These findings have contributed to research into relationships between G.L.P-1 receptor signaling and cardiovascular outcomes.
Research reference: Marso SP, et al. (2016). Sema (G.L.P) and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
5. Peptide Structure and Stability Research
Sema (G.L.P) is also studied in peptide engineering.
Its chemical structure provides a useful example of how amino acid substitutions and fatty acid conjugation can influence the behavior of a peptide molecule.
Researchers may compare Sema (G.L.P) with natural G.L.P-1 and other modified analogs when investigating enzymatic resistance, receptor interaction, and molecular stability.
Sema (G.L.P) 30mg Research Vial
The Sema (G.L.P) 30mg compound listed by Orion Peptide is intended for laboratory researchers who require a larger nominal quantity of the compound.
The 30mg designation describes the quantity associated with the compound presentation. It does not represent a clinical dose, administration schedule, or FDA-approved dosage form.
A research laboratory selecting this compound should consider its analytical requirements, experimental design, and available quality documentation.
Researchers should verify the batch identity, peptide content, purity, and handling requirements before introducing the material into experimental work.
Sema (G.L.P) 30mg Purity and Certificate of Analysis
Peptide quality is an important consideration in research involving receptor signaling or molecular analysis.
Impurities, degradation compounds, and differences in peptide content can affect the interpretation of experimental findings.
At
Orion Peptide, compound quality information should be supported by batch-specific analytical documentation rather than general purity statements.
HPLC Purity Analysis
High-performance liquid chromatography (HPLC) is commonly used to separate a peptide from detectable related substances.
HPLC results can provide information about chromatographic purity.
A reported purity percentage should always be associated with the actual tested batch.
Mass Spectrometry
Mass spectrometry helps determine whether the measured molecular mass is consistent with the expected Sema (G.L.P) structure.
It complements HPLC testing by providing information about molecular identity.
What Should a Sema (G.L.P) COA Include?
A useful Certificate of Analysis should identify:
- The compound and batch number
- The testing date
- The laboratory responsible for the analysis
- HPLC purity results
- Molecular identity information
- Assay or peptide content results, when available
- Relevant test methods and acceptance criteria
A reported HPLC purity of 99% does not automatically demonstrate that a vial contains 99% peptide by mass.
Purity, actual peptide content, and sterility are separate quality characteristics.
For this reason, researchers should review all available batch documentation before using the material.
Sema (G.L.P) 30mg Storage and Handling
Sema (G.L.P) stability depends on its formulation, physical state, packaging, and storage conditions.
Research-grade Sema (G.L.P) may be supplied as a lyophilized powder. This process removes water from the material and can help maintain peptide stability under appropriate conditions.
However, lyophilization does not guarantee stability for a particular period.
Researchers should follow the validated storage recommendations supplied with the specific batch.
General laboratory precautions include:
- Keeping peptide containers protected from moisture and unnecessary light exposure.
- Maintaining the storage conditions specified by the supplier.
- Avoiding repeated temperature changes.
- Using clearly labeled containers.
- Following institutional laboratory handling procedures.
The stability of Sema (G.L.P) after dissolution depends on several factors, including solvent composition, temperature, concentration, and container compatibility.
Clinical storage instructions for FDA-approved Sema (G.L.P) medicines should not automatically be applied to an independently manufactured research-grade compound.
Frequently Asked Questions About Sema (G.L.P) 30mg
What is Sema (G.L.P) 30mg?
Sema (G.L.P) 30mg is a research compound containing a nominal 30mg quantity of Sema (G.L.P), a synthetic G.L.P-1 receptor agonist. It is intended for controlled laboratory research and analytical investigation.
What is Sema (G.L.P) used for in research?
Sema (G.L.P) is investigated in studies of G.L.P-1 receptor signaling, insulin secretion, glucagon regulation, appetite-related pathways, and peptide pharmacology.
What is the molecular formula of Sema (G.L.P)?
The molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉, and the molecular weight is approximately 4,113.58 g/mol.
How many amino acids does Sema (G.L.P) contain?
Sema (G.L.P) contains 31 amino acid residues. Its structure also includes modifications that increase resistance to enzymatic degradation and promote albumin binding.
What is the half-life of Sema (G.L.P)?
Sema (G.L.P) has an elimination half-life of approximately one week in humans, based on pharmacokinetic studies of pharmaceutical Sema (G.L.P).
What is the difference between Sema (G.L.P) and natural G.L.P-1?
Natural G.L.P-1 is rapidly degraded by enzymes such as DPP-4. Sema (G.L.P) contains structural changes that improve resistance to degradation and extend circulation time.
Is Sema (G.L.P) 30mg an FDA-approved dosage?
No. The 30mg research vial sold by Orion Peptide is not an FDA-approved dosage form. FDA-approved Sema (G.L.P) medicines are separate regulated pharmaceutical compounds.
How can researchers verify Sema (G.L.P) purity?
Researchers can review a batch-specific COA containing HPLC purity data, mass spectrometry results, and relevant peptide content measurements.
Does 99% purity mean the vial contains exactly 30mg of Sema (G.L.P)?
No. HPLC purity and actual peptide content are different measurements. A separate quantitative assay may be needed to confirm the amount of Sema (G.L.P) present.
How should Sema (G.L.P) 30mg be stored?
Storage conditions should follow the manufacturer’s validated recommendations for the specific compound and batch. Stability depends on whether the material is lyophilized or dissolved, as well as its packaging and formulation.
Important Research Disclaimer
Sema (G.L.P) 30mg offered by Orion Peptide is intended exclusively for legitimate laboratory research.
This research compound is not approved by the FDA for human or veterinary administration, diagnosis, treatment, prevention of disease, or dietary supplementation.
Although Sema (G.L.P) is the active ingredient in certain FDA-approved medicines, the regulatory approval of those medicines does not extend to independently manufactured research-grade vials.
Published clinical findings do not establish the quality, safety, sterility, or clinical suitability of this compound.
The FDA has warned about unapproved G.L.P-1 compounds marketed under research-use-only labels and sold for human consumption.
All research involving this material must comply with applicable laws, institutional requirements, and laboratory safety procedures.
Scientific References
- Lau J, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (G.L.P-1) Analogue Sema (G.L.P). Journal of Medicinal Chemistry, 58(18), 7370–7380. PubMed. DOI: 10.1021/acs.jmedchem.5b00726.
- Marso SP, et al. (2016). Sema (G.L.P) and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375, 1834–1844. Research paper.
- Wilding JPH, et al. (2021). Once-Weekly Sema (G.L.P) in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002. PubMed. DOI: 10.1056/NEJMoa2032183.
- Knudsen LB, Lau J. (2019). The Discovery and Development of Liraglutide and Sema (G.L.P). Frontiers in Endocrinology, 10, 155. Full research review.
- National Center for Biotechnology Information. PubChem Compound Summary for Sema (G.L.P), CID 56843331. PubChem.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved G.L.P-1 Drugs Used for Weight Loss. FDA safety information.
